Literature DB >> 24777276

Risk of relapse phenotype recurrence in multiple sclerosis.

Tomas Kalincik1, Katherine Buzzard2, Vilija Jokubaitis3, Maria Trojano4, Pierre Duquette5, Guillermo Izquierdo6, Marc Girard5, Alessandra Lugaresi7, Pierre Grammond8, Francois Grand'Maison9, Celia Oreja-Guevara10, Cavit Boz11, Raymond Hupperts12, Thor Petersen13, Giorgio Giuliani14, Gerardo Iuliano15, Jeannette Lechner-Scott16, Michael Barnett17, Roberto Bergamaschi17, Vincent Van Pesch17, Maria Pia Amato17, Erik van Munster17, Ricardo Fernandez-Bolanos17, Freek Verheul17, Marcela Fiol17, Edgardo Cristiano17, Mark Slee17, Maria Edite Rio17, Daniele Spitaleri18, Raed Alroughani17, Orla Gray17, Maria Laura Saladino17, Sholmo Flechter17, Joseph Herbert17, Jose Antonio Cabrera-Gomez17, Norbert Vella17, Mark Paine17, Cameron Shaw17, Fraser Moore17, Steve Vucic17, Aldo Savino17, Bhim Singhal17, Tatjana Petkovska-Boskova17, John Parratt17, Carmen-Adella Sirbu17, Csilla Rozsa17, Danny Liew17, Helmut Butzkueven19.   

Abstract

OBJECTIVES: The aim was to analyse risk of relapse phenotype recurrence in multiple sclerosis and to characterise the effect of demographic and clinical features on this phenotype.
METHODS: Information about relapses was collected using MSBase, an international observational registry. Associations between relapse phenotypes and history of similar relapses or patient characteristics were tested with multivariable logistic regression models. Tendency of relapse phenotypes to recur sequentially was assessed with principal component analysis.
RESULTS: Among 14,969 eligible patients (89,949 patient-years), 49,279 phenotypically characterised relapses were recorded. Visual and brainstem relapses occurred more frequently in early disease and in younger patients. Sensory relapses were more frequent in early or non-progressive disease. Pyramidal, sphincter and cerebellar relapses were more common in older patients and in progressive disease. Women presented more often with sensory or visual symptoms. Men were more prone to pyramidal, brainstem and cerebellar relapses. Importantly, relapse phenotype was predicted by the phenotypes of previous relapses. (OR = 1.8-5, p = 10(-14)). Sensory, visual and brainstem relapses showed better recovery than other relapse phenotypes. Relapse severity increased and the ability to recover decreased with age or more advanced disease.
CONCLUSION: Relapse phenotype was associated with demographic and clinical characteristics, with phenotypic recurrence significantly more common than expected by chance.
© The Author(s), 2014.

Entities:  

Keywords:  MSBase; Multiple sclerosis; phenotype; presentation of neurological diseases; prognosis

Mesh:

Year:  2014        PMID: 24777276     DOI: 10.1177/1352458514528762

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  19 in total

1.  A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data.

Authors:  Tim Spelman; Orla Gray; Robyn Lucas; Helmut Butzkueven
Journal:  J Vis Exp       Date:  2015-12-09       Impact factor: 1.355

2.  Assessment and Treatment Strategies for a Multiple Sclerosis Relapse.

Authors:  Cynthia Wang; America Ruiz; Yang Mao-Draayer
Journal:  J Immunol Clin Res       Date:  2016-12-07

3.  Temporal trends of multiple sclerosis disease activity: Electronic health records indicators.

Authors:  Liang Liang; Nicole Kim; Jue Hou; Tianrun Cai; Kumar Dahal; Chen Lin; Sean Finan; Guergana Savovoa; Mattia Rosso; Mariann Polgar-Tucsanyi; Howard Weiner; Tanuja Chitnis; Tianxi Cai; Zongqi Xia
Journal:  Mult Scler Relat Disord       Date:  2021-10-24       Impact factor: 4.339

4.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

5.  Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis: A Retrospective Monocentric Analysis.

Authors:  Nic Skorupka; Andrei Miclea; Katarzyna Aleksandra Jalowiec; Christoph Bocksrucker; Nicole Kamber; Andrew Chan; Behrouz Mansouri Taleghani; Robert Hoepner; Anke Salmen
Journal:  Transfus Med Hemother       Date:  2019-11-14       Impact factor: 3.747

6.  Comparative efficacy of switching to natalizumab in active multiple sclerosis.

Authors:  Timothy Spelman; Tomas Kalincik; Annie Zhang; Fabio Pellegrini; Heinz Wiendl; Ludwig Kappos; Larisa Tsvetkova; Shibeshih Belachew; Robert Hyde; Freek Verheul; Francois Grand-Maison; Guillermo Izquierdo; Pierre Grammond; Pierre Duquette; Alessandra Lugaresi; Jeannette Lechner-Scott; Celia Oreja-Guevara; Raymond Hupperts; Thor Petersen; Michael Barnett; Maria Trojano; Helmut Butzkueven
Journal:  Ann Clin Transl Neurol       Date:  2015-02-27       Impact factor: 4.511

Review 7.  Cerebellar Dysfunction in Multiple Sclerosis.

Authors:  Alastair Wilkins
Journal:  Front Neurol       Date:  2017-06-28       Impact factor: 4.003

Review 8.  Primary Progressive Multiple Sclerosis: Putting Together the Puzzle.

Authors:  Ahmed Abdelhak; Martin S Weber; Hayrettin Tumani
Journal:  Front Neurol       Date:  2017-05-31       Impact factor: 4.003

Review 9.  Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.

Authors:  Elizabeth A Mills; Ali Mirza; Yang Mao-Draayer
Journal:  Front Neurol       Date:  2017-03-29       Impact factor: 4.003

10.  Treatment choices and neuropsychological symptoms of a large cohort of early MS.

Authors:  Olga von Bismarck; Theresa Dankowski; Björn Ambrosius; Nicole Hessler; Gisela Antony; Andreas Ziegler; Muna-Miriam Hoshi; Lilian Aly; Felix Luessi; Sergiu Groppa; Luisa Klotz; Sven G Meuth; Björn Tackenberg; Muriel Stoppe; Florian Then Bergh; Hayrettin Tumani; Tania Kümpfel; Martin Stangel; Christoph Heesen; Brigitte Wildemann; Friedemann Paul; Antonios Bayas; Clemens Warnke; Frank Weber; Ralf A Linker; Ulf Ziemann; Uwe K Zettl; Frauke Zipp; Heinz Wiendl; Bernhard Hemmer; Ralf Gold; Anke Salmen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.